Flagship Biosciences LLC to present morphometric analysis of cardiac infarct tissue with digital pathology

Dec 2009

Flagship Biosciences to present at the American Heart Association

Boulder, CO – December 6, 2009 – Flagship Biosciences LLC,(Flagship) will present the use of digital pathology in morphometric analysis of heart infarct tissue at the American Heart Association annual meeting in Miami Florida. The presentation is titled Antibody to Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Number of Activated Tissue Macrophages and Improves Left Ventricular Function Following Myocardial Infarction in a Rat Coronary-Artery Ligation Model

Flagship Biosciences is a pathologist-owned company focused on utilizing whole slide imaging for quantitative pathology in pharmaceutical and device applications.

READY TO TAKE THE NEXT STEP?

Our Services

Pharma

Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.

Clinical Diagnostics

Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.

We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.

During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.

We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.

Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.

Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.

The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.

NEWS

Dec 2009

READY TO TAKE THE NEXT STEP?

Our Services

Pharma

Clinical Diagnostics

Related Resources

Blog

Posters & Publications

News

Thanks for your interest in Flagship Biosciences.

Thanks for your interest in Flagship Biosciences.

Start Your Consultation Today